Gene linked to Alzheimer’s plays indirect role in increasing delirium risk
Speech and language metrics, eye movements, and pupillary movements are also useful in detecting degeneration in multiple networks. Autonomic nervous system function is reflected by measures like heart rate, heart rate variability, sleep patterns due to disruption of circadian rhythms, and even social and mood changes may all be potentially detected by wearable sensors.
The researchers will be using information from several studies that are ongoing, hoping that by applying artificial intelligence (AI) to the data to get a prototype up and running over the next three years.
Beyond the enormous amount of work involved in predicting AD in the preclinical stages, developing consumer devices capable of reliable sensing, and analyzing the data, extensive studies will be required to provide an accurate measure of variability between subjects and at various times in the same person. Data security is also crucial in this aspect. The project
The project is partly funded by philanthropist Bill Gates, and partly owes some of its budget to the UK government which wants to use AI on data to prevent chronic diseases and understand how they work. The project will begin work with the UK's Alan Turing Institute, the premier national institute for data science and artificial intelligence.
This part of the project will see the collection of reams of data from studies into AD that are still going on at present. This is because, in the words of the Institute's Chris Holmes, "Artificial intelligence has the potential to transform the learning opportunities from large-scale data studies such as Edon by integrating information from multiple sources. We will use AI to deliver new insights into the early signals of disease by combining digital data measurements with traditional sources such as brain imaging and memory tests."
The idea is to come up with a "digital fingerprint" that can be read using a wearable technology or a smartphone app, thus ensuring that people who are at most risk for several chronic medical conditions, can be identified early for appropriate interventions. The aim is to detect the very first changes in the brain, which would help arrest many of these conditions before they lead to dementia, and the person becomes, in many cases, unable to live normally.
The study will draw volunteers from the 2019 project called Accelerating Detection of Disease Program. This is targeting 5 million volunteers to help change the way disease is diagnosed, using the data they provide on AD, cancer, and heart disease. AI will help detect patterns that will, in turn, help identify AD.
The researchers want to classify and analyze this to understand what signs of the disease occur earlier in its course so that in the future, there will be an early warning system. Previous studies have indicated the feasibility of this as an inexpensive, multicentre home-based approach to monitoring patients more efficiently while still reducing the burden on the healthcare network. It could also boost the efficiency of clinical trials. Sources: Wakefield, J. (2020). Wearable to spot Alzheimer's being developed. https://www.bbc.com/news/technology-51474115 Medicaldevice-network.com. (2018). Wearable devices may offer alternative for Alzheimer's diagnosis. https://www.medicaldevice-network.com/news/wearable-devices-may-offer-alternative-alzheimers-diagnosis/ Kourtis, L.C., Regele, O.B., Wright, J.M. et al. Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. npj Digital Med 2, 9 (2019). https://doi.org/10.1038/s41746-019-0084-2 . Kourtis, L.C., Regele, O.B., Wright, J.M. et al. Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. npj Digital Med 2, 9 (2019). https://doi.org/10.1038/s41746-019-0084-2 . https://www.nature.com/articles/s41746-019-0084-2#article-info
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology